ADHD-Europe

You are here: Home News Successful Kick-off for large research programme on aggression (4-6/11/2013)
  • Decrease font size
  • Default font size
  • Increase font size
Successful Kick-off for large research programme on aggression (4-6/11/2013) Print

With a very intensive and inspiring two day meeting, the international Aggressotype research programme was successfully kicked-off in Madrid from November 4 to 6. Aggressotype is a large EU-funded project on pathological aggression in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and conduct disorder (CD). The programme receives 6 Mio Euro from the EU in the next 5 years to study the biological underpinnings of aggression and to develop novel prediction and treatment strategies. With 60 delegates representing 23 academic and private sector partners from 11 countries, Aggressotype is one of the largest programmes on aggression world-wide. Amongst the attending delegates were also a representative of the European patient support group ADHD-Europe, which will take part in the Ethics Board of Aggressotype, and US-based and Dutch leading experts from the Scientific Advisory Board of the Aggressotype programme, who gave inspiring talks during the meeting.

In stimulating and fruitful discussions the meeting delegates finalized plans for a total of 12 comprehensive and highly complementary work packages. These will include molecular and neuroimaging studies of the genetics, epigenetics and neural correlates of aggression. In addition to this, the behavioural components of impulsive and instrumental types of aggression will be examined, and the Aggressotype programme will work towards novel treatment and prevention strategies for maladaptive aggression.

More than 5.4 million children in Europe suffer from ADHD and/or CD, and costs for their treatment amount to over 6.2 billion Euro per year. Pathological aggression is common in CD, but multiple studies also show increased prevalence of aggression problems in ADHD, further adding to the burden of patients, their families, the victims of aggression, and society as a whole. The strong, multidisciplinary team of preclinical and clinical top researchers in the Aggressotype programme hopes to significantly improve the lives of patients and their families in several ways. On the shorter term the team’s research will clarify the effectiveness of existing stimulant treatment for aggression and lead to the development of non-pharmacological biofeedback therapy for the prevention of aggression escalation. On the longer term, the elucidation of the mechanisms underlying aggression within Aggressotype will allow for the development of entirely new pharmacological interventions and more individualized treatment tailored to the needs of individual patients. The Aggressotype team feels that only such comprehensive approaches can relieve the personal, economical, and societal burden of maladaptive aggression.

With a very intensive and inspiring two day meeting, the international Aggressotype research programme was successfully kicked-off in Madrid from November 4 to 6. Aggressotype is a large EU-funded project on pathological aggression in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and conduct disorder (CD). The programme receives 6 Mio Euro from the EU in the next 5 years to study the biological underpinnings of aggression and to develop novel prediction and treatment strategies. With 60 delegates representing 23 academic and private sector partners from 11 countries, Aggressotype is one of the largest programmes on aggression world-wide. Amongst the attending delegates were also a representative of the European patient support group ADHD-Europe, which will take part in the Ethics Board of Aggressotype, and US-based and Dutch leading experts from the Scientific Advisory Board of the Aggressotype programme, who gave inspiring talks during the meeting.
In stimulating and fruitful discussions the meeting delegates finalized plans for a total of 12 comprehensive and highly complementary work packages. These will include molecular and neuroimaging studies of the genetics, epigenetics and neural correlates of aggression. In addition to this, the behavioural components of impulsive and instrumental types of aggression will be examined, and the Aggressotype programme will work towards novel treatment and prevention strategies for maladaptive aggression.
More than 5.4 million children in Europe suffer from ADHD and/or CD, and costs for their treatment amount to over 6.2 billion Euro per year. Pathological aggression is common in CD, but multiple studies also show increased prevalence of aggression problems in ADHD, further adding to the burden of patients, their families, the victims of aggression, and society as a whole. The strong, multidisciplinary team of preclinical and clinical top researchers in the Aggressotype programme hopes to significantly improve the lives of patients and their families in several ways. On the shorter term the team’s research will clarify the effectiveness of existing stimulant treatment for aggression and lead to the development of non-pharmacological biofeedback therapy for the prevention of aggression escalation. On the longer term, the elucidation of the mechanisms underlying aggression within Aggressotype will allow for the development of entirely new pharmacological interventions and more individualized treatment tailored to the needs of individual patients. The Aggressotype team feels that only such comprehensive approaches can relieve the personal, economical, and societal burden of maladaptive aggression.

agressotype Gruppenbild Kick-off2

 

 



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.